Drug interactions
Ocrelizumab + Ublituximab
Severity: Major
Ocrelizumab and Ublituximab: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both are anti-CD20 monoclonal antibodies that deplete B cells. Using them together offers no recognised benefit and adds immunosuppression, raising the risk of serious infections and hypogammaglobulinemia.
What this interaction means in plain words
Ocrelizumab and Ublituximab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Ocrelizumab belongs to Central Nervous System; Ublituximab belongs to Miscellaneous.
Why it happens
Additive B-cell depletion from two anti-CD20 antibodies causes cumulative immunosuppression.
What to do
Avoid concurrent use; do not combine the two anti-CD20 agents. When switching, monitor for infection and consider the long duration of B-cell depletion from the first agent.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ocrelizumab and Ublituximab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ocrelizumab
- Adenovirus types 4 and 7 live + Ocrelizumab Contraindicated
- Influenza virus vaccine quadrivalent intranasal + Ocrelizumab Contraindicated
- Measles mumps and rubella vaccine live + Ocrelizumab Contraindicated
- Measles mumps rubella and varicella vaccine live + Ocrelizumab Contraindicated
- Measles vaccine + Ocrelizumab Contraindicated
- Anti-thymocyte + Ocrelizumab Major
Other interactions of Ublituximab
Frequently asked questions
Can I take Ocrelizumab with Ublituximab?
MediHelp rates the interaction as major. Ocrelizumab and Ublituximab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both are anti-CD20 monoclonal antibodies that deplete B cells. Using them together offers no recognised benefit and adds immunosuppression, raising the risk of serious infections and hypogammaglobulinemia.
How serious is the interaction between Ocrelizumab and Ublituximab?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use; do not combine the two anti-CD20 agents. When switching, monitor for infection and consider the long duration of B-cell depletion from the first agent.
What other medicines interact with Ocrelizumab?
MediHelp also lists interactions of Ocrelizumab with, for example, Adenovirus types 4 and 7 live, Influenza virus vaccine quadrivalent intranasal, Measles mumps and rubella vaccine live. The full list is on the Ocrelizumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
